Economic reception in 2017 with Dr. Edmund Stoiber

More than 100 companies participated in the event at Faculty Club of the IZB.

Group-picture- Dr. Peter Hanns Zobel_Kerstin-Schreyer_Dr. Edmund Stoiber

Dr. Peter Hanns Zobel, CEO, Fördergesellschaft IZB mbH, Kerstin Schreyer, Parliament Member, Dr. Edmund Stoiber,  Minister President of Bavaria (retired)

Over 100 guests came to the economic reception, which took place on October 25, 2017, now for the fifth time. Every year the parliament member Kerstin Schreyer invites companies from her constituency and from the IZB. This year’s speaker was the former Minister President of Bavaria, Dr. Edmund Stoiber. The Managing Director of the IZB, Dr. Peter Hanns Zobel, warmly welcomed the “spiritual father of the IZB” and presented some successful financings to him and the guests, for example Rigontec GmbH and Immunic AG.
“I am pleased to be here today, because as Bavarian Prime Minister, I helped with the birth of the Innovation and Start-up Center for Biotechnology (IZB),” explained Dr. Stoiber at the beginning of his speech. “At the opening of the IZB in 1995, I emphasized that we wanted to develop Martinsried into Europe’s first biotechnology center – in competition with Paris, Oxford and Milan. We succeeded! Today, “Martinsried” is synonymous with state-of-the-art biotechnology,” said Stoiber delightedly.

“Today, “Martinsried” is synonymous with state-of-the-art biotechnology.“

Dr. Edmund Stoiber,
Minister President of Bavaria (retired)

”In the mid-nineties, the challenges for Bavaria as a business location had progressively grown as a result of globalization and the development of new technologies. As a policy decision, I decided at that time to privatize state-owned enterprises and to invest the revenue amounting to billions in the context of “Offensive Future Bavaria”. At that time, there were already some life science institutions in Planegg and Munich-Grosshadern – the University Hospital Grosshadern and the Max Planck Institute for Biochemistry. It therefore made sense to give young, innovative companies in the biotech industry a chance here, to form a cluster. The IZB arose out of this idea,” said Stoiber describing the development of the location. After the enthusiastic speech by Dr. Stoiber an entertaining evening developed with numerous discussions. “It always surprises me how companies from the most diverse areas make contacts at the reception and subsequently carry out projects together,” said Schreyer.


Dr. Martin Ried, Dr. Michael Schaeffer, both CRELUX GmbH – a WuXi AppTec company, Dr. Stefan Strobl, BioNTech Small Molecules GmbH, ­Dr. Daniel Vitt, Immunic AG (f.l.t.r.)

Adrian Passow_and_Dr. Luitpold Fried

Adrian Passow, Omegametrix GmbH,  ­
Dr. Luitpold Fried, Dust Biosolutions GmbH (f.l.t.r.)